FORMULATIONS FOR TREATING CLUSTER SYMPTOMS ASSOCIATED WITH AUTISM SPECTRUM DISORDER
The present disclosure provides for pharmaceutical compositions useful for treating autism spectrum disorder. The pharmaceutical compositions comprise particular THC:CBD ratios and terpene profiles, which have been demonstrated effective at treating cluster symptoms associated with autism spectrum disorder.
1 . A pharmaceutical composition for the treatment of autism spectrum disorder (ASD), comprising:
(a) a Cannabinoid Profile comprising two or more cannabinoids, wherein the two or more cannabinoids comprise Tetrahydrocannabinol (THC) and Cannabidiol (CBD) at a THC:CBD ratio of 1:1 by weight; and
(b) a Terpene Profile comprising α-Pinene, Valencene, and Eucalyptol.
2 . The pharmaceutical composition of claim 1 , wherein the Terpene Profile comprises 25%-35% α-Pinene by weight, 25%-35% Valencene by weight, and 30%-40% Eucalyptol by weight, wherein the total of % of α-Pinene, +% Valencene+% Eucalyptol=100%.
3 . The pharmaceutical composition of claim 1 , wherein the Terpene Profile comprises about 31% Pinene by weight, about 31% Valencene by weight, and about 37.5% Eucalyptol by weight.
4 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises olive oil.
5 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.
6 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated as a liquid dose.
7 . The pharmaceutical composition of claim 6 , wherein the liquid dose comprises about 2.5 mL.
8 . The pharmaceutical composition of claim 6 , wherein the liquid dose comprises about 5 mL.
9 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is peppermint flavored, chocolate flavored, grapefruit flavored, vanilla flavored, lemon flavored, ginger, orange flavored, or a combination thereof.
10 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition reduces agitation in patients with ASD.
11 . A pharmaceutical composition for the treatment of autism spectrum disorder (ASD), comprising:
(a) a Cannabinoid Profile comprising two or more cannabinoids, wherein the two or more cannabinoids comprise Tetrahydrocannabinol (THC) and Cannabidiol (CBD) at a THC:CBD ratio of 5:1 by weight; and
(b) a Terpene Profile comprising β-caryophyllene (BCP), Myrcene, and α-Bisabolol.
12 . The pharmaceutical composition of claim 11 , wherein the Terpene Profile comprises 20%-40% BCP by weight, 20%-40% Myrcene by weight, and 20%-40% α-Bisabolol by weight, wherein the total of % of α-Pinene, +% Valencene+% Eucalyptol=100%.
13 . The pharmaceutical composition of claim 11 , wherein the Terpene Profile comprises about 33% by weight BCP, about 34% by weight Myrcene, and about 33% by weight a-Bisabolol.
14 . The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition comprises olive oil.
15 . The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition is formulated for oral administration.
16 . The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition is formulated as a liquid dose.
17 . The pharmaceutical composition of claim 16 , wherein the liquid dose comprises about 2.5 mL.
18 . The pharmaceutical composition of claim 16 , wherein the liquid dose comprises about 5 mL.
19 . The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition is grapefruit flavored, vanilla flavored, chocolate flavored, peppermint flavored, lemon flavored, ginger, orange flavored, or a combination thereof.
20 . The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition improves communication behavior or reduces self-stimulatory behavior in patients with autism spectrum disorder (ASD).